RecruitingPhase 1NCT06392477
A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma
Studying B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sanofi
- Principal Investigator
- Clinical Sciences & OperationsSanofi
- Intervention
- SAR448501(drug)
- Enrollment
- 96 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (16)
- Investigational Site Number : 001-203, Camperdown, New South Wales, Australia
- Investigational Site Number : 001-202, Townsville, Queensland, Australia
- Investigational Site Number : 001-205, Adelaide, South Australia, Australia
- Investigational Site Number : 001-204, Melbourne, Victoria, Australia
- Investigational Site Number : 001-201, Perth, Western Australia, Australia
- Investigational Site Number : 001-703, Kamenitz, Serbia
- Investigational Site Number : 001-601, Singapore, Singapore
- Investigational Site Number : 001-602, Singapore, Singapore
- Investigational Site Number : 001-401, Busan, South Korea
- Investigational Site Number : 001-403, Busan, South Korea
- Investigational Site Number : 001-404, Goyang-si, South Korea
- Investigational Site Number : 001-402, Seoul, South Korea
- Investigational Site Number : 001-405, Seoul, South Korea
- Investigational Site Number : 001-503, Changhua, Taiwan
- Investigational Site Number : 001-502, Kaohsiung City, Taiwan
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06392477 on ClinicalTrials.govOther trials for B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07133997Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic LeukemiaCity of Hope Medical Center
- RECRUITINGPHASE1NCT07361224Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.Tel-Aviv Sourasky Medical Center
- RECRUITINGPHASE2NCT07523737Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell LymphomaBeijing Tongren Hospital
- RECRUITINGPHASE1, PHASE2NCT07283679Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaM.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07135466A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell MalignanciesSheba Medical Center
- ACTIVE NOT RECRUITINGPHASE2NCT07480850Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell LymphomaCancer Institute and Hospital, Chinese Academy of Medical Sciences
- ACTIVE NOT RECRUITINGNCT07480837Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin LymphomaCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGEARLY PHASE1NCT07376642A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin LymphomaSuzhou Immunofoco Biotechnology Co., Ltd